Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome

NCT02295475 is registered in ClinicalTrials.gov with Scott C. Woller, MD as lead sponsor.

NCT NCT02295475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02295475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Lead sponsor
Scott C. Woller, MD
Phase
Phase 4
Overall status
Completed
Start date
December 10, 2014
Completion date
March 31, 2022
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome, thrombosis